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ABSTRACT: Under development are new techniques that have
the potential to define subpopulations of patients which may or
may not respond to targeted therapy. Better definition of resis-
tance mechanisms against monoclonal antibodies or tyrosine
kinase inhibitors will be one approach to achieve this goal. Pro-
gress has been made in the detection of these mechanisms when
targeting the epidermal growth factor (EGF) receptor family. Pro-
teomics either performed by imaging techniques or by methods
such as matrix-assisted desorption/ionisation time-of-flight
(MALDI-TOF) mass spectrometry requires further standardisation
and validation. A mass spectroscopy-based pre-treatment patient
selection system is under development that is highly reproducible
and capable of classifying patients by survival.
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Only a fraction of patients respond initially to therapy (primary
resistance), and those who do, often lose their response to tar-
geted therapy with time (secondary resistance). The postulated
mechanisms behind targeted therapy and development of resis-
tance were explored and the epidermal growth factor receptor
(EGFR) family was used as an example. The ErbB or epidermal
growth factor (EGF) family of receptor tyrosine kinases consists
of four members: EGFR (Erb1/HER-1), HER-2 (ErbB1/neu), HER-3
(ErbB3), and HER-4 (ErbB4). ErbB receptor tyrosine kinases are
attractive targets for therapy. They initiate multiple signalling
pathways, and they are conveniently accessible on the cell sur-
face where they can be targeted with monoclonal antibodies.1
They have an ATP-binding site and are amenable to enzymatic
blockade. Mutations - often single amino acid replacements and
short deletions – in ErbB receptor genes can occur, as is the case
with non-small-cell lung cancer (NSCLC). Likewise, overexpres-
sion of ErbB proteins occurs in a fraction of carcinomas, including
ErbB-2 overexpression in about a third of breast cancers. Cetux-
imab (Erbitux), panitumumab (Vectibix) and trastuzumab (Her-
ceptin) are all examples of anti-ErbB monoclonal antibodies in
clinical use. The potential mechanisms of trastuzumab action
include
– recruitment of natural killer (NK) cells to Her-2 overexpressing
tumour cells;
– reduction of Her-2 signalling to the phosphatidylinositol-3
kinase (PI3K), Src, or mTOR pathways;
– inhibition of angiogenesis and vasculature normalisation,
thereby improving delivery of chemotherapeutic drugs such
as paclitaxel (Taxol);
– enhancing receptor endocytosis and degradation;
– other hypothesised mechanisms.
Perhaps the main mechanism of action is antibody-depen-
dent cellular cytotoxicity (ADCC) of tumour cells. Antibodies
attach to the tumour cell, then NK cells move in and destroy it.
Clynes compared knockout and wild-type mice and showed that
preferential activation of inhibitory Fc receptors enhanced
tumour responses to trastuzumab treatment.2 Mice without Fc
receptors were unable to recruit NK cells, hence the antibody dis-
played only partial inhibition of tumour growth.
Spiridon and colleagues used mice with severe combined
immune deficiency (SCID) to demonstrate synergistic anti-
tumour effect of a combination of monoclonal antibodies against
Her-2 that do not bind to the same epitope.3 The speaker pre-
sented studies performed in his laboratory, in collaboration with
M. Sela, showing that single monoclonal antibodies lead to some
down-regulation and degradation of EGFR, but certain combina-
tions completely destroy the receptor. A single monoclonal anti-
body leads only to dimer formation, yielding inefficient
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internalisation, whereas multiple monoclonal antibodies lead to
efficient internationalisation by formation of an antigen–antibody
lattice at the cell surface.
An example was shown that involved combining two mono-
clonal antibodies, trastuzumab and pertuzumab, which do not
compete for the same HER-2 site. The combination was much
more effective than either used alone.
DEVELOPMENT OF RESISTANCE TO ANTI-ERBB RECEPTOR
ANTIBODIES: Only a third of breast cancer patients with Her-2
overexpressing tumours respond initially to trastuzumab, imply-
ing that most patients have primary resistance. Also the majority
of responding patients demonstrate disease progression after
months of treatment initiation because they develop secondary
resistance. Nagata et al. described the development of resistance
to monoclonal antibodies via deficiency of PTEN, a dual phospha-
tase that mainly dephosphorylates position D3 of membrane
phosphatidylinositol-3,4,5 trisphosphate. PTEN-deficient breast
cancer patients had significantly poorer responses to trast-
uzumab-based therapy than those with normal PTEN levels.
The authors concluded that PTEN deficiency predicted resistance
to trastuzumab and that PI3K inhibitors rescued PTEN loss-
induced trastuzumab resistance in a model system, suggesting
PI3K-targeting therapies as a means of overcoming acquired
resistance.4
Another possible mechanism for resistance to monoclonal
antibodies against tyrosine kinase receptors was described by
Nagy et al. who claimed that MUC4, a membrane-associated gly-
coprotein that inhibits trastuzumab binding to Her-2, was higher
in a trastuzumab-resistant cell line than in sensitive cell lines.5
Levels of MUC4 were inversely correlated with the trastuzumab-
binding capacity of single cells. Knockdown of MUC4 expression
by RNA interference increased binding. It is postulated that mask-
ing of ErbB2 by MUC4 is a mechanism for trastuzumab resistance.
In addition resistance may occur via insulin-like growth factor-I
(IGF-I) receptor interactions, as described by Nahta and col-
leagues.6 They found that Her-2 interacts in a unique way with
IGF-I receptor in trastuzumab-resistant cells possibly enabling
cross talk between IGF-I receptor and Her-2. The IGF-I receptor/
Her-2 heterodimer could contribute to trastuzumab resistance
and serve as a potential therapeutic target in breast cancer
patients whose disease has progressed while on trastuzumab.5
In conclusion, defective immune responses (e.g. Fc receptors)
might underlie primary resistance to trastuzumab, but acquired
(secondary) resistance seems to involve compensatory signalling
mechanisms.
Various reports have addressed the issue of resistance to tyro-
sine kinase inhibitors (TKI). Despite significant responses to gefi-
tinib (Iressa), most patients with non-small-cell lung cancer
(NSCLC) relapse after 6–18 months. Kobayashi et al. described
the case of a patient with EGFR-mutant, gefitinib-responsive,
advanced NSCLC who relapsed after 2 years of complete remis-
sion. Secondary resistance developed via a second point mutation
in EGFR.7 This phenomenon might be responsible for germ-line
mutations in families with multiple cases of NSCLC. It is not
known whether this mutation exists independent of gefitinib
exposure. Acquired resistance to lapatinib was associated with
up-regulation of oestrogen receptor signalling.8 These findings
appear to provide a rationale for preventing the development of
acquired resistance by simultaneously inhibiting both oestrogen
receptor and ErbB2 signalling pathways.
In summary tumours demonstrate remarkable plasticity,
seeming to switch pathways when one is effectively inhibited.
Clarifying the mechanisms of drug action is critical for under-
standing resistance to targeted therapies. Resistance mecha-
nisms richly harness compensatory pathways (PI3K/Akt, Her-3
and IGF-I receptor). Understanding drug resistance will likely
identify novel drug combinations and elucidate the mechanisms
of tumour cell escape, which must involve the ability to up-regu-
late certain pathways.
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